Supernus Pharmaceuticals, Inc.
NYSE/NASDAQ:SUPNPharmaRockville, Maryland, United States · Est. 2005 · 200 employees
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for central nervous system disorders.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
12
Indications↗
Distinct diseases across all programs
71
Clinical Trials↗
All sponsored trials (all statuses)
6
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Approved1
Phase 32
Phase 23
Preclinical1
By Therapeutic Area
top 2
Neurology
350%
Psychiatry
233%
R&D Momentum
35/100
Pipeline Velocity
6/100
Trial Completion Rate
88/100
Pipeline Concentration
39/100
Pipeline Freshness
37/100
Strategic Signals
- ↗Active in Psychiatry but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Aug 3, 20268-K8-K
Aug 3, 20268-KFORM 8-K
Aug 3, 20268-KFORM 8-K
Aug 3, 20268-KFORM 8-K
Jul 22, 20268-K8-K
Jul 16, 2026TrialOpen-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
Jun 18, 20268-K8-K
4 more events
Jun 18, 20268-KSUPERNUS PHARMACEUTICALS, INC. (SUPN) (CIK 0001356576)
Jan 19, 2026TrialDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
Jul 30, 2025TrialSPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
Dec 30, 2024TrialRENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
Details
Company Info
Company Overview
$700.0M
Mkt Cap
$302.2M
Revenue
$75.1M
Cash
CEOJack Khattar
Founded2005
Employees200
HQRockville, Maryland, United States
ExchangeNYSE/NASDAQ:SUPN
Websitesupernus.com
LinkedInCompany Page
Therapeutic Focus
PsychiatryNeurology
Recent SEC Filings
8-KAug 3, 2026
8-K
8-KAug 3, 2026
FORM 8-K
8-KAug 3, 2026
FORM 8-K
8-KAug 3, 2026
FORM 8-K
8-KJul 22, 2026
8-K
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neurology
Neurology
Parkinson Disease
KynmobiApproved
Parkinson's
KynmobiPreclinical
Progressive Supranuclear Palsy
KynmobiPreclinical
Psychiatry
Unknown / Other
Regulatory
Regulatory Timeline
20211 event
FDAApr 2
Qelbree — QELBREE
Application NDA211964 (NDA)
20267 events
SECAug 3
8-K
Accession: 0001356576-26-000035
SECAug 3
FORM 8-K
Accession: 0001104659-26-089839
SECAug 3
FORM 8-K
Accession: 0001104659-26-089524
SECAug 3
FORM 8-K
Accession: 0001104659-26-089425
SECJul 22
8-K
Accession: 0001356576-26-000031
SECJun 18
8-K
Accession: 0001356576-26-000028
SECJun 18
SUPERNUS PHARMACEUTICALS, INC. (SUPN) (CIK 0001356576)
Accession: 001-35518
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)